Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels

Haematologica. 2020 Jan;105(1):e22-e25. doi: 10.3324/haematol.2018.212597. Epub 2019 May 2.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adenine / analogs & derivatives
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Cytokines
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Piperidines
  • Plasma

Substances

  • Antibodies, Monoclonal, Humanized
  • Cytokines
  • Piperidines
  • ibrutinib
  • Adenine
  • obinutuzumab